PEDIATRICS Vol. 70 No. 3 September 1982, pp. 354-356
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mehta, P.
Right arrow Articles by Albiol, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, P.
Right arrow Articles by Albiol, L.

Prostacyclin and Platelet Aggregation in Sickle Cell Disease

Paulette Mehta MD1 and Loreto Albiol MD1

1 Department of Pediatrics, Division of Hematology-Oncology, University of Florida College of Medicine, Gainesville

Patients with sickle cell disease have been described to have decreased platelet aggregation. The cause of this decrease is believed to be the refractory state of platelets from continual in vivo activation. In this study, plasma 6-keto PGF1agr (stable metabolite of vessel wall-derived prostaglandin, prostacyclin) levels were measured to study the mechanism of decreased platelet aggregation. Plasma 6-keto PGF1agr levels were measured by radioimmunoassay in ten patients with sickle cell disease and in ten control subjects. Plasma 6-keto PGF1agr levels in normal subjects ranged from 0 to 100 pg/ml (mean 40 ± 14 pg/ml), but were significantly higher in patients with sickle cell disease (range 170 to 880 pg/ml, mean 446 ± 89 pg/ml, P < .002). Platelet aggregation in response to an endoperoxide analog in these patients was lower compared with that of the control subjects. This study suggests that prostacyclin activity is increased in subjects with sickle cell disease. This increased activity is probably due to persistent stress to the endothelium from hemolysis and continual platelet activation. Decreased platelet aggregation seen in these patients may be due to elevated prostacyclin activity.

Submitted on May 4, 1981
Accepted on August 24, 1981